Cencora closes $3.0 billion senior notes offering in five tranches due 2029 to 2056
Cencora closed an underwritten public offering of $3.0 billion in senior notes on February 13, 2026, with maturities from 2029 to 2056. The company intends to use the net proceeds to repay amounts outstanding under a 364-day term credit agreement dated January 12, 2026, which helped fund its acquisition of OneOncology, and any remaining proceeds for general corporate purposes. The notes add to the company's debt, and the filing states they are unsecured and rank equal with its other unsecured debt.
Key points
- Five tranches total $3.0 billion: $500 million due 2029 at 3.950%, $500 million due 2030 at 4.250%, $500 million due 2033 at 4.600%, $1.0 billion due 2036 at 4.900%, and $500 million due 2056 at 5.650%.
- Net proceeds are intended to repay the 364-day term credit agreement dated January 12, 2026, used partly to fund the OneOncology acquisition.
- The notes are unsecured and structurally subordinated to liabilities of the company's subsidiaries, including trade payables.
- Interest is payable semiannually, starting May 15, 2026 for the 2030 notes and August 13, 2026 for the other tranches.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 13, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.